CordenPharma

CordenPharma is a global contract development and manufacturing organization (CDMO) established in 2006, providing integrated solutions for pharmaceutical and biotechnology companies. The firm specializes in complex modalities, including peptides, oligonucleotides, lipids, and highly potent compounds. By offering end-to-end services across the drug development lifecycle, CordenPharma supports clients from early-stage formulation and process development through to large-scale cGMP manufacturing and commercialization. Their technical infrastructure enables the production of sophisticated drug substances and drug products, ensuring compliance with stringent global regulatory standards.

Operating with a workforce of 1,000-5,000 employees across 8 global locations, the company maintains a robust operational footprint. Meet CordenPharma's team to understand the leadership and scientific expertise driving their manufacturing excellence. The organization leverages advanced technologies to facilitate drug delivery, oncology applications, and complex dosage forms. Their service model emphasizes transparency and cost-effectiveness, providing pharmaceutical partners with the necessary technical support to navigate the complexities of modern drug development and supply chain management.

CordenPharma distinguishes itself through a comprehensive service continuum that includes packaging, regulatory filing support, and specialized manufacturing services. By integrating scientific research with industrial-scale production, the company addresses critical needs in the pharmaceutical sector. Their expertise in small molecule synthesis and injectable drug delivery positions them as a key partner for firms requiring high-quality, scalable manufacturing solutions. With a focus on innovation and technical precision, CordenPharma continues to expand its capabilities to meet the evolving demands of the global healthcare and biotechnology markets.